Strategies for Neuroprotection, Relapse Prevention, and Mortality Reduction in Patients with Schizophrenia

Only a minority of patients with schizophrenia consistently adhere to their oral antipsychotics. Long-acting injectable (LAI) formulations of antipsychotics improve patient outcomes through both neuroprotection and improved adherence. To ensure that more patients with schizophrenia are offered the opportunity to take LAIs, clinicians who provide psychiatric care must possess accurate information about this important treatment option. In this activity, an expert faculty member will discuss the safety and tolerability of LAIs; their role in the treatment of first-episode psychosis, as well as later in the course of schizophrenia; the selection of an LAI; and strategies for discussing the option of LAIs with patients. Two patient cases will be presented to illustrate the use of LAIs in common clinical scenarios.